SUMMARY A method for quantitating the liver, bone, intestinal and placental alkaline phosphatase activity of serum, using an algorithm for converting selective inactivation by guanidine hydrochloride, L-phenylalanine, and heat into equivalent isoenzyme activity is described. it is our belief and that of other workers' that the analytical potential of selective inhibition techniques has been unnecessarily overlooked.
In the clinical biochemistry laboratory an increased serum alkaline phosphatase activity [EC 3 it is our belief and that of other workers' that the analytical potential of selective inhibition techniques has been unnecessarily overlooked.
In a previous paper4 the usefulness of a new reagent Accepted for publication 26 March 1986 for inhibition studies, guanidine hydrochloride, was described. In this paper further selective inhibition techniques entailing the use of heat' and Lphenylalanine' were combined with the use of guanidine hydrochloride to develop an algorithm for the direct quantitation of alkaline phosphatase isoenzymes, including any placental or carcinoplacental alkaline phosphatase. The possible contribution of these fractions in chemical inhibition studies has been noted but not resolved by earlier investigators.7
Material and methods
ALKALINE PHOSPHATASE ISOENZYMES
The sources of the four major isoenzymes of alkaline phosphatase were as described previously.4 Final concentrations of L-phenylalanine investigated were 2 5 mmol/l (0 41 g/l), 5 mmol/l (0-83 g/l), 10mmol/l (1-65g/l), 20mmol/l (3 30g/l), and 50 mmol/l (8-26 g/l). Alkaline phosphatase activity remaining in the presence of L-phenylalanine was determined in duplicate for each isoenzyme on the Cobas Bio, using the instrument settings shown in table I (column A)-that is, the same settings as those used for the determination of total alkaline phosphatase.
HEAT STABILITY STUDIES
The resistance of alkaline phosphatase isoenzyme fractions to heating at 65°C for 10 minutes was studied.3 Plastic sample cups for the Cobas Bio were prewarmed to 650C in a water bath (Grant Instruments, Cambridge, England). Sample (100p1) was added to each cup at 15 second intervals and incubated at 65°C for exactly 10 minutes. Serum was used in preference to plasma to avoid fibrinogen precipitation at this temperature. Immediately after incubation cups were placed directly on ice for exactly one minute and then stored at 4°C until analysis. Alkaline phosphatase activity remaining after heat treatment was determined in duplicate for each isoenzyme fraction using the instrument settings listed in table I (column A).
Results

INHIBITION WITH GUANIDINE HYDROCHLORIDE
For all four isoenzymes used in this study similar inhibition to that previously described,4 with 0-3 mol/l guanidine hydrochloride, was found-that is, 14%, 47%, 90%, and 124% of the total activity remained in the presence of this inhibitor for the bone, liver, intestinal and placental isoenzymes, respectively.
INHIBITION WITH L-PHENYLALANINE
In contrast to guanidine hydrochloride, the noncompetitive inhibition observed for each isoenzyme with L-phenylalanine was linear with time (figure) for all concentrations of this reagent investigated; such analyses were performed using the instrument settings listed in table I (column C). Quantitative methodfor determining serum alkaline phosphatase isoenzyme activity Table 2 shows the percentage activity remaining for each isoenzyme in the presence of varying concentrations of L-phenylalanine. For the intestinal fraction, the percentage activity remaining in the presence of 2 5, 5 , and 1Ommol/l L-phenylalanine was shown to be independent of the temperature at which the reaction was carried out (25°C, 30°C, or 37°C).
L-Phenylalanine (10 mmol/l) was selected as the concentration of choice for this inhibitor. At this concentration, optimal discrimination between the bone and liver isoenzymes, on the one hand, and the intestinal and placental fractions on the other was observed; furthermore, the total activity of both bone and liver isoenzymes was reduced by only 14% at this concentration.
HEAT STABILITY STUDIES
Bone, liver, intestinal and placental isoenzymes, each separately diluted with saline to about 1000 U/1, were heated at 65°C. After heat treatment bone and liver isoenzyme activity was completely destroyed after two and a half minutes, while the placental fraction retained total activity for more than 10 minutes.
The intestinal isoenzyme, diluted in saline, showed partial resistance to the effect of heat, with 55%, 30%, and 10% of the total activity remaining after heating for two and a half minutes, five, and 10 minutes, respectively. This intestinal sample was then further diluted in saline to obtain samples with activities of 500, 250, and 50 U/1; on heating these samples for 10 minutes, some activity remained; the percentage activity remaining being inversely related to the activity of intestinal alkaline phosphatase.
To resolve this unexpected finding the use of an alternative diluent was investigated. A serum based diluent with zero alkaline phosphatase activity was prepared using heat inactivation. Intestinal samples with a similar concentration range to those in saline were prepared using this diluent and then subjected to heat treatment. In contrast to the results found using saline as diluent, zero activity remained in all intestinal samples prepared using a serum based diluent. This has also been our experience with all undiluted patient sera containing intestinal alkaline phosphatase. Previous workers have shown that maintenance of pH is critical in heat stability studies.5 Vari- Table 3 Percentage inactivation of bone, liver, intestinal and placental isoenzymes diluted to various activities using both serum and saline Bone  1000  86  86  14  13  0  0  500  86  87  13  14  0  0  250  85  86  15  14  0  0  50  86  85  14  15  0  0  Liver  1000  86  86  47  47  0  0  500  86  85  48  47  0  0  250  86  86  47  48  0  0  50  85  86  46  47  0  0  Intestinal  1000  33  33  90  89  10  0  500  34  35  91  88  16  0  250  33  33  89  89  20  0  50  34  33  91  91  38  0  Placental  1000  68  68  124  124  100  100  500  70  68  122  126  100  100  250  69  67  123  124  100  100  80  68  69  125  122  100  100 group.bmj.com on October 29, 2017 -Published by http://jcp.bmj.com/ Downloaded from Table 4 summarises the mean response of each isoenzyme to guanidine hydrochloride, L-phenylalanine, and heat (under the reaction conditions specified).
ALGORITHM FOR THE RESOLUTION OF ALKALINE PHOSPHATASE ISOENZYMES
Based on the assumption that the total alkaline phosShephard, Peake, Walmsley phatase activity (T) is the sum of the bone (B), liver (L), intestinal (I) and placental (P) fractions, and that the heat stable fraction (H), guanidine hydrochloride stable fraction (G), and L-phenylalanine stable fraction (A) similarly represent the sum of the relative contribution of individual isoenzyme components, the following set of equations summarise these responses:
T =B + L + I + P H = lOOP G = 124P + 090I + 047L + 0-14B A = 0-36P + 0-33I + 0-86L + 0.86B By solving these equations in the sequence placental, intestinal, liver, and bone, the following algorithm for the quantitative determination of each alkaline phosphatase isoenzyme fraction can be derived:
ABILITY OF METHOD TO RESOLVE ISOENZYME MIXTURES Guanidine hydrochloride and L-phenylalanine inhibition and heat stability studies were then carried out in duplicate on each individual isoenzyme fraction and on mixtures of these isoenzymes. Table 5 documents the stability of each isoenzyme and mixtures of isoenzymes to each method of inactivation. The ability of the algorithm to resolve these isoenzyme mixtures was then tested; the results found using the algorithm were compared with the expected results (table 6) and show that for these mixtures the isoenzyme composition could be resolved to within + 3%. Day to day precision studies were carried out using a 50% bone:50% liver mixture and a 50% intestinal:50% placental mixture; the results summarised in table 7 show that the method has acceptable reproducibility. No placental isoenzyme was detected in these normal subjects.
rised into one of three groups: (i) In 80 patients the source and cause of the raised serum alkaline phosphatase activity was established through clinical diagnosis and other pathology tests. In all these cases the isoenzyme results were compatible with the clinical diagnosis. (ii) In 10 patients the source of the raised alkaline phosphatase activity was clinically unknown. The source was identified by isoenzyme analysis, which in turn led to further clinical investigations and a firm diagnosis being made. The raised serum alkaline phosphatase activity and the hepatomegaly suggested liver disease. The normal ALT values, however, made this diagnosis doubtful. To investigate this problem further the serum sample with a total alkaline phosphatase of 251 U/I was then subjected to inhibition using heat, L-phenylalanine, and guanidine hydrochloride under the final reaction conditions specified. The activity remaining after treatment was as follows: heat (65°C for 10 minutes) 0 U/l; L-Phenylalanine (10 mmol/l) 216 U/l; guanidine hydrochloride (0 3 mol/1) 59 U/1.
Application of the algorithm resulted in the following activities for each isoenzyme: placental, 0 U/I (reference range 0); intestinal, 2 U/I (1%) (reference range 0-15); liver, 72 U/I (29%) (reference range 16-74); bone, 177 U/i (71%) (reference range Selective inhibition with heat, L-phenylalanine, and guanidine hydrochloride gave the following results of remaining activity: heat (65°C for 10 minutes) 98 U/l; I-phenylalanine (10 mmol/l) 125 U/1; guanidine hydrochloride (0 3 mol/l) 161 U/1.
Application of the algorithm resulted in the following activities for each isoenzyme: placental, 98U/I (49%) (reference range 0); intestinal, 0 U/I (0%) (reference range 0-15); liver, 76 U/I (37%) (reference range 16-74); bone, 28U/l (14%) (reference range 8-60). Thus placental alkaline phosphatase activity was the principal component, and no significant abnormalities in liver or bone isoenzyme activities were detected.
In contrast with earlier three isoenzyme methods,7 8 the placental alkaline phosphatase activity of 98 U/I does not interfere with the measurement of other isoenzymes using our method, because its activity has been carefully measured using heat inhibition and the activity of placental alkaline phosphatase using Lphenylalanine and guanidine hydrochloride has been included in our algorithm. Failure to do this will firstly result in placental alkaline phosphatase activity being measured as intestinal (although it might reasonably be assumed that this is mostly placental in serum from a pregnant subject, as both these forms of alkaline phosphatase exhibit similar stability to Lphenylalanine). The liver component, however, will be grossly overestimated and the bone component underestimated due to the greater stability of placental alkaline phosphatase to guanidine hydrochloride (or urea) than the liver isoenzyme. Table 10 shows the errors introduced in a three isoenzyme algorithm.
A three isoenzyme method thus suggests a raised liver isoenzyme activity and a negative bone isoenzyme activity. The advantage of the proposed method in the presence of either suspected or unsuspected placental or carcinoplacental alkaline phosphatase becomes clear.
Conclusion
In summary, rapid and reproducible methods for the determination of guanidine hydrochloride, L-phenylalanine, and heat stable alkaline phosphatase activities were developed using the Cobas Bio centrifugal analyzer at 37°C. Using a simple mathematical algo- 76  191  Bone  28  -81  Total  202 202 rithm, these activities were used to quantitatively determine the contribution ofeach isoenzyme fraction to the total alkaline phosphatase activity.
As the total activity, L-phenylalanine stable, and heat stable activities can all be performed in a single analytical run on the Cobas Bio, the total analysis time for the quantitative determination of alkaline phosphatase isoenzymes was about 30 minutes.
The ability of the method to accurately resolve mixtures of isoenzymes, including placental alkaline phosphatase, was confirmed. Age and sex related reference ranges for each isoenzyme fraction were determined. The method was validated in a study of over 100 patients and was shown to be clinically useful in a variety of situations.
